Markus Weber

Markus Weber

Auto-generated profile, based on publicly available information

Markus Weber

Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St. Gallen, St. Gallen, Switzerland

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2024 in European Journal of Neurology
Verified
Journal Article
Open access
PDPhilip Van Damme
Philip Van Damme
AAAmmar Al-Chalabi
Ammar Al-Chalabi
PAPeter M. Andersen
Peter M. Andersen
ACAdriano Chiò
Adriano Chiò
PCPhilippe Couratier
Philippe Couratier
MWMarkus Weber
Markus Weber
Background: This update of the guideline on the management of amyotrophic lateral sclerosis (ALS) was commissioned by the European Academy of Neurology (EAN) and prepared in collaboration with the European Reference Network for Neuromuscular Diseases (ERN EURO‐NMD) and the support of the European Network for the Cure ALS (ENCALS) and the European Organization for Professionals and Patients with ALS (EUpALS).Methods: Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess the effectiveness of interventions for ALS. Two systematic reviewers from Cochrane Response supported the guideline panel. The working group identified a total of 26 research questions, performed systematic reviews, assessed the quality of the available evidence, and made specific recommendations. Expert consensus statements were provided where insufficient evidence was available.Results: A guideline mapping effort revealed only one other ALS guideline that used GRADE methodology (a National Institute for Health and Care Excellence [NICE] guideline). The available evidence was scarce for many research questions. Of the 26 research questions evaluated, the NICE recommendations could be adapted for 8 questions. Other recommendations required updates of existing systematic reviews or de novo reviews. Recommendations were made on currently available disease‐modifying treatments, multidisciplinary care, nutritional and respiratory support, communication aids, psychological support, treatments for common ALS symptoms (e.g., muscle cramps, spasticity, pseudobulbar affect, thick mucus, sialorrhea, pain), and end‐of‐life management.Conclusions: This update of the guideline using GRADE methodology provides a framework for the management of ALS. The treatment landscape is changing rapidly, and further updates will be prepared when additional evidence becomes available.

23 February 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
PHPaul J. Hop
Paul J. Hop
RZRamona A.J. Zwamborn
Ramona A.J. Zwamborn
EHEilis Hannon
Eilis Hannon
GSGemma L. Shireby
Gemma L. Shireby
MNMarta F. Nabais
Marta F. Nabais
GSGeorge Davey Smith
George Davey Smith
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with an estimated heritability between 40 and 50%. DNA methylation patterns can serve as proxies of (past) exposures and disease progression, as well as providing a potential mechanism that mediates genetic or environmental risk. Here, we present a blood-based epigenome-wide association study meta-analysis in 9706 samples passing stringent quality control (6763 patients, 2943 controls). We identified a total of 45 differentially methylated positions (DMPs) annotated to 42 genes, which are enriched for pathways and traits related to metabolism, cholesterol biosynthesis, and immunity. We then tested 39 DNA methylation–based proxies of putative ALS risk factors and found that high-density lipoprotein cholesterol, body mass index, white blood cell proportions, and alcohol intake were independently associated with ALS. Integration of these results with our latest genome-wide association study showed that cholesterol biosynthesis was potentially causally related to ALS. Last, DNA methylation at several DMPs and blood cell proportion estimates derived from DNA methylation data were associated with survival rate in patients, suggesting that they might represent indicators of underlying disease processes potentially amenable to therapeutic interventions.

20 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSalim Megat
Salim Megat
NMNatalia Mora
Natalia Mora
JSJason Sanogo
Jason Sanogo
OROlga Roman
Olga Roman
ACAlberto Catanese
Alberto Catanese
LDLuc Dupuis
Luc Dupuis
Amyotrophic lateral sclerosis (ALS) has substantial heritability, in part shared with fronto-temporal dementia (FTD). We show that ALS heritability is enriched in splicing variants and in binding sites of 6 RNA-binding proteins including TDP-43 and FUS. A transcriptome wide association study (TWAS) identified 6 loci associated with ALS, including inNUP50encoding for the nucleopore basket protein NUP50. Independently, rare variants inNUP50were associated with ALS risk (P = 3.71.10−03; odds ratio = 3.29; 95%CI, 1.37 to 7.87) in a cohort of 9,390 ALS/FTD patients and 4,594 controls. Cells from one patient carrying aNUP50frameshift mutation displayed a decreased level of NUP50. Loss of NUP50 leads to death of cultured neurons, and motor defects inDrosophilaand zebrafish. Thus, our study identifies alterations in splicing in neurons as critical in ALS and provides genetic evidence linking nuclear pore defects to ALS.

1 May 2013 in Neurobiology of Aging
Verified
Journal Article
Open access
WRWouter van Rheenen
Wouter van Rheenen
FDFrank P. Diekstra
Frank P. Diekstra
PDPerry T.C. van Doormaal
Perry T.C. van Doormaal
MSMeinie Seelen
Meinie Seelen
KKKevin Kenna
Kevin Kenna
LBLudo Van Den Bosch
Ludo Van Den Bosch
The H63D polymorphism in HFE has frequently been associated with susceptibility to amyotrophic lateral sclerosis (ALS). Regarding the role of HFE in iron homeostasis, iron accumulation is considered an important process in ALS. Furthermore, novel therapeutic strategies are being developed targeting this process. Evidence for this genetic association is, however, limited to several small studies. For this reason we studied the H63D polymorphism in a large European cohort including 3962 ALS patients and 5072 control subjects from 7 countries. After meta-analysis of previous studies and current findings we conclude that the H63D polymorphism in HFE is not associated with susceptibility to ALS, age at disease onset, or survival.

31 March 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PHPaul J. Hop
Paul J. Hop
MKMaarten Kooyman
Maarten Kooyman
BKBrendan J. Kenna
Brendan J. Kenna
RZRamona A. J. Zwamborn
Ramona A. J. Zwamborn
KEKristel R. van Eijk
Kristel R. van Eijk
JVJan H. Veldink
Jan H. Veldink
Amyotrophic lateral sclerosis (ALS) is a heritable disorder where rare variants with low-to-moderate penetrance are thought to dominate genetic risk. To identify such rare variants, we harmonized and analyzed exome data from 22 cohorts, totaling 17,919 individuals with ALS and 200,703 controls across discovery and replication phases. Rare variant analyses identified several new risk genes, with replication confirming association of YKT6 and supporting HTR3C , GBGT1 and KNTC1 . We also provide strong, independent validation for genes with limited previous evidence: ARPP21 , DNAJC7 and CFAP410 . Notably, in ARPP21 , we identified a new high-effect variant (p.P747L) and confirmed that p.P563L is an ALS-associated variant leading to an aggressive disease course. Beyond new discoveries, our analyses largely recapitulated the known genetic architecture of ALS, identifying risk variants in over 20% of cases and supporting a cumulative oligogenic risk model. These findings highlight new translational targets and show that rare variant analyses capture substantially more genetic risk than common variant genome-wide association studies.

1 January 1999 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
AEAndrew Eisen
Andrew Eisen
MWMarkus Weber
Markus Weber